CureVac N.V.
$4.66+0.00%(+$0.00)
TickerSpark Score
78/100
77
Valuation
100
Profitability
100
Growth
84
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CVAC research report →
52-Week Range67% of range
Low $2.48
Current $4.66
High $5.72
Companywww.curevac.com
CureVac N. V. , a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
- CEO
- Alexander Zehnder
- IPO
- 2020
- Employees
- 825
- HQ
- Tübingen, DE
Price Chart
+28.73% · this period
Valuation
- Market Cap
- $1.05B
- P/E
- 7.00
- P/S
- 12.75
- P/B
- 1.04
- EV/EBITDA
- 2.88
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 93.00%
- Op Margin
- 212.01%
- Net Margin
- 182.11%
- ROE
- 18.40%
- ROIC
- 13.53%
Growth & Income
- Revenue
- $535.18M · 895.54%
- Net Income
- $162.19M · 162.34%
- EPS
- $0.72 · 161.02%
- Op Income
- $177.68M
- FCF YoY
- 125.82%
Performance & Tape
- 52W High
- $5.72
- 52W Low
- $2.48
- 50D MA
- $4.97
- 200D MA
- $4.85
- Beta
- 1.84
- Avg Volume
- 1.17M
Get TickerSpark's AI analysis on CVAC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CVAC Coverage
We haven't published any research on CVAC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CVAC Report →Similar Companies
NVAX+4.16%
Novavax, Inc.
$9.27
NKTR+2.83%
Nektar Therapeutics
$69.49
SNDX+3.98%
Syndax Pharmaceuticals, Inc.
$20.13
INBX+0.46%
Inhibrx Biosciences, Inc.
$110.01
AMLX+6.83%
Amylyx Pharmaceuticals, Inc.
$13.61
IMTX+4.86%
Immatics N.V.
$11.22
RLAY+7.87%
Relay Therapeutics, Inc.
$13.02
ORIC+5.52%
ORIC Pharmaceuticals, Inc.
$8.41